JCR Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 3/6

JCR Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 25.4% ve 3.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 25.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 7.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

25.4%

Kazanç büyüme oranı

25.4%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	13.2%
Gelir büyüme oranı	3.2%
Gelecekteki özkaynak getirisi	7.8%
Analist kapsamı	Good
Son güncelleme	31 Oct 2024

Gelecekteki son büyüme güncellemeleri

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

Aug 03

Recent updates

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Sep 06

What JCR Pharmaceuticals Co., Ltd.'s (TSE:4552) 32% Share Price Gain Is Not Telling You

Sep 04

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Aug 23

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Aug 09

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

Aug 03

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

Jul 26

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Jul 12

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

May 22

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Mar 18

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Feb 29

Kazanç ve Gelir Büyüme Tahminleri

TSE:4552 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (JPY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	41,724	5,196	4,181	N/A	7
3/31/2026	41,215	4,801	7,283	N/A	7
3/31/2025	41,563	5,069	9,780	N/A	7
9/30/2024	35,256	-437	N/A	N/A	N/A
6/30/2024	40,208	4,098	N/A	N/A	N/A
3/31/2024	42,871	5,507	7,217	9,312	N/A
12/31/2023	41,365	5,364	N/A	N/A	N/A
9/30/2023	43,034	8,063	-9,017	-952	N/A
6/30/2023	35,545	4,014	N/A	N/A	N/A
3/31/2023	34,343	3,772	-14,060	-5,500	N/A
12/31/2022	37,508	5,154	N/A	N/A	N/A
9/30/2022	38,280	6,235	4,857	13,009	N/A
6/30/2022	50,875	14,343	N/A	N/A	N/A
3/31/2022	51,082	14,507	-2,044	9,289	N/A
12/31/2021	50,931	16,549	N/A	N/A	N/A
9/30/2021	47,517	14,899	-6,495	1,362	N/A
6/30/2021	34,717	7,657	N/A	N/A	N/A
3/31/2021	30,085	6,892	2,814	10,341	N/A
12/31/2020	26,128	4,137	N/A	N/A	N/A
9/30/2020	24,496	2,983	1,040	6,210	N/A
6/30/2020	24,807	3,076	N/A	N/A	N/A
3/31/2020	24,781	2,678	89	4,927	N/A
12/31/2019	25,709	3,653	N/A	N/A	N/A
9/30/2019	24,121	3,260	11	4,482	N/A
6/30/2019	23,638	3,802	N/A	N/A	N/A
3/31/2019	23,160	3,715	3,010	3,905	N/A
12/31/2018	20,874	2,454	N/A	N/A	N/A
9/30/2018	20,682	2,566	2,710	3,675	N/A
6/30/2018	20,885	2,857	N/A	N/A	N/A
3/31/2018	20,594	3,070	N/A	3,133	N/A
12/31/2017	20,233	2,930	N/A	N/A	N/A
9/30/2017	19,738	2,722	N/A	2,572	N/A
6/30/2017	18,670	2,079	N/A	N/A	N/A
3/31/2017	18,085	1,863	N/A	2,651	N/A
12/31/2016	17,483	1,668	N/A	N/A	N/A
9/30/2016	17,190	1,751	N/A	1,017	N/A
6/30/2016	17,091	1,620	N/A	N/A	N/A
3/31/2016	17,438	1,789	N/A	2,201	N/A
12/31/2015	17,594	2,299	N/A	N/A	N/A
9/30/2015	17,482	2,281	N/A	2,853	N/A
6/30/2015	17,192	1,861	N/A	N/A	N/A
3/31/2015	16,855	1,682	N/A	499	N/A
12/31/2014	16,380	1,066	N/A	N/A	N/A
9/30/2014	16,516	1,319	N/A	2,795	N/A
6/30/2014	16,117	1,316	N/A	N/A	N/A
3/31/2014	15,705	1,296	N/A	4,565	N/A
12/31/2013	15,669	1,517	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 4552 önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 0.3% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: 4552 önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: 4552 önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: 4552 şirketinin gelirinin (yıllık 3.2% ) JP pazarından (yıllık 4.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 4552 şirketinin gelirinin (yıllık 3.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 4552 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 7.8 %).

JCR Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

Consensus EPS estimates fall by 17%

Price target decreased by 10% to JP¥1,314

Price target decreased by 10% to JP¥1,657

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Consensus EPS estimates increase by 13%

Recent updates

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA

JCR Pharmaceuticals Co., Ltd. Announces Interim Dividend

JCR Pharmaceuticals Co., Ltd. Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

What JCR Pharmaceuticals Co., Ltd.'s (TSE:4552) 32% Share Price Gain Is Not Telling You

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Investor sentiment deteriorates as stock falls 17%

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

First quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd Announces Discontinuation of TEMCELL HS Inj. Expanded Indication Development for Neonatal Hypoxic Ischemic Encephalopathy

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Final dividend of JP¥10.00 announced

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

Consensus EPS estimates fall by 17%

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Price target decreased by 10% to JP¥1,314

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Investor sentiment deteriorates as stock falls 22%

Full year 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index (USD)

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Now 22% overvalued

JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Price target decreased by 10% to JP¥1,657

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Jan 26, 2024

New major risk - Share price stability

JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)

Upcoming dividend of JP¥10.00 per share at 1.5% yield

Investor sentiment improves as stock rises 18%

PHC IVD and JCR Announce GROWJECTOR® Duo

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Oct 25, 2023

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Consensus EPS estimates increase by 13%

First quarter 2024 earnings released: EPS: JP¥12.90 (vs JP¥11.05 in 1Q 2023)

Price target decreased by 7.4% to JP¥1,859

JCR Receives Approval to Start Global Phase I/II Clinical Trial for JR-441 for the Treatment of Mucopolysaccharidosis Type III A (MPS IIIA)

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Receives an Approval for Expanded Indication of Growject®? in Short Stature Due to SHOX-Deficiency

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 20%

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Jul 26, 2023

Consensus EPS estimates fall by 24%

Full year 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued after recent price drop

Consensus revenue estimates fall by 17%

Upcoming dividend of JP¥10.00 per share at 1.3% yield

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023